What is HC Wainwright’s Forecast for Senseonics Q1 Earnings?

Senseonics Holdings, Inc. (NYSE:SENS) – Research analysts at HC Wainwright reduced their Q1 2026 earnings per share estimates for shares of Senseonics in a report issued on Tuesday, March 3rd. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.67) per share for the quarter, down from their prior forecast of ($0.49). HC Wainwright currently has a “Buy” rating and a $18.50 target price on the stock. The consensus estimate for Senseonics’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Senseonics’ Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($3.12) EPS, FY2028 earnings at ($2.72) EPS and FY2029 earnings at ($2.03) EPS.

Other research analysts have also recently issued reports about the company. Barclays reissued an “overweight” rating and issued a $31.00 target price (up from $1.50) on shares of Senseonics in a research note on Wednesday, November 5th. TD Cowen restated a “buy” rating on shares of Senseonics in a report on Thursday, January 8th. Finally, Stifel Nicolaus set a $9.00 price target on shares of Senseonics in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $22.70.

Senseonics Trading Up 0.7%

Shares of NYSE SENS opened at $6.87 on Thursday. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. Senseonics has a twelve month low of $5.25 and a twelve month high of $15.74. The company’s fifty day moving average is $7.20 and its 200-day moving average is $7.55. The stock has a market cap of $280.70 million, a price-to-earnings ratio of -52.85 and a beta of 0.99.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Aristides Capital LLC bought a new stake in Senseonics during the 4th quarter worth about $139,000. Virtu Financial LLC bought a new stake in Senseonics during the fourth quarter worth about $188,000. Quadrature Capital Ltd acquired a new position in Senseonics during the fourth quarter valued at approximately $321,000. Balyasny Asset Management L.P. bought a new position in Senseonics in the fourth quarter valued at approximately $91,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Senseonics during the 4th quarter worth approximately $972,000. Institutional investors own 12.36% of the company’s stock.

Senseonics News Roundup

Here are the key news stories impacting Senseonics this week:

• Positive Sentiment: Company guidance: Senseonics updated FY2026 revenue guidance to $58.0M–$62.0M, above the consensus revenue estimate of ~$50.3M — a near-term revenue beat that supports top-line growth expectations. Company / MarketBeat
• Neutral Sentiment: Street upside thesis: A recent Zacks write-up highlights a consensus price-target implying ~124.5% upside for SENS — a reminder that some analysts see significant long-term valuation upside, though such aggregated targets are not a guarantee. Wall Street Analysts Predict a 124.49% Upside in Senseonics (SENS)
• Neutral Sentiment: HC Wainwright still rates SENS a “Buy” with an $18.50 price target — the firm’s rating and target imply confidence in the longer-term story despite the cuts to earnings. HC Wainwright / MarketBeat
• Negative Sentiment: Major EPS downgrades: HC Wainwright significantly lowered EPS across Q1–Q4 2026 and pushed down FY2026–FY2029 (and issued an FY2030 estimate), e.g., FY2026 EPS cut to ($2.95) from ($2.27) and multi-year losses deepened — these revisions weaken near- and medium-term profitability expectations and are the primary driver of today’s share weakness. HC Wainwright cuts summary / MarketBeat

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.